Clinical trial
Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias
NCT00410423 · Sidney Kimmel Cancer Center at Thomas Jefferson University, Other · Completed
Key facts
| NCT number | NCT00410423 |
|---|---|
| Title | Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias |
| Official title | Phase I/II Trial of VELCADE® (Bortezomib) in Combination With Mitoxantrone and Etoposide for Relapsed or Refractory Acute Leukemias |
| Lead sponsor | Sidney Kimmel Cancer Center at Thomas Jefferson University, Other |
| Collaborators | Millennium Pharmaceuticals, Inc. Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Relapsed Acute Leukemia, Refractory Acute Leukemia |
| Intervention type | Drug |
| Interventions | Bortezomib with mitoxantrone, etoposide and cytarabine, Bortezomib 1.0mg/m^2, Bortezomib 1.3mg/m^2 |
| Enrollment | 55 |
| Start date | Jan 1, 2006 |
| Primary completion | May 1, 2013 |
| Completion | Sep 1, 2014 |
| First posted | Dec 12, 2006 |
| Last update posted | Apr 30, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: